- Home
- RMM vs LFCR Comparison
RMM vs LFCR Comparison
Compare RMM & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$8.76
Company Overview
Basic Information| Metric | RMM | LFCR |
|---|---|---|
| Founded | 2019 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.7M | 308.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RMM | LFCR |
|---|---|---|
| Price | $13.83 | $8.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 66.5K | ★ 132.3K |
| Earning Date | 01-01-0001 | 01-02-2026 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | ★ $128,867,000.00 |
| Revenue This Year | N/A | $2.80 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | $15.55 | ★ N/A |
| Revenue Growth | N/A | ★ 0.47 |
| 52 Week Low | $12.32 | $4.76 |
| 52 Week High | $16.10 | $8.85 |
Technical Indicators
Market Signals| Indicator | RMM | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 68.89 |
| Support Level | $13.52 | $7.95 |
| Resistance Level | $14.09 | $8.75 |
| Average True Range (ATR) | 0.12 | 0.36 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 39.98 | 97.39 |
Price Performance
Historical Comparison RMM
LFCR
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.